Quick Answer
BriaCell Therapeutics Corp. reported Cash and Equivalents of $10.49 million for fiscal year 2025.
BriaCell Therapeutics Corp. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $10.49M | +1117.3% |
| 2024 | $862.1K | -95.9% |
| 2023 | $21.25M | -48.2% |
| 2022 | $41.04M | -28.3% |
| 2021 | $57.27M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| October 31, 2025 | $2.71M | -53.1% | -74.1% |
| July 31, 2025 | $10.49M | +1117.3% | -15.8% |
| April 30, 2025 | $12.46M | +1231.7% | +148.5% |
| January 31, 2025 | $5.01M | -19.7% | -13.4% |
| October 31, 2024 | $5.79M | -57.6% | +571.9% |
| July 31, 2024 | $862.1K | -95.9% | -7.9% |
| April 30, 2024 | $935.7K | -96.7% | -85.0% |
| January 31, 2024 | $6.24M | -81.4% | -54.2% |
- BriaCell Therapeutics Corp. showed an increase of +1117.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, BriaCell Therapeutics Corp.’s cash and equivalents has declined by 81.7% (from $57.27 million to $10.49 million).
- The most recent figure is from BriaCell Therapeutics Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on October 16, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: